IPR-803
- Product Name
- IPR-803
- CAS No.
- 892243-35-5
- Chemical Name
- IPR-803
- Synonyms
- IPR-803;IPR-803, 10 mM in DMSO;Benzoic acid, 3-[[3-(hexahydro-1H-azepin-1-yl)-6-oxo-6H-anthra[1,9-cd]isoxazol-5-yl]amino]-;inhibit,IPR 803,Inhibitor,IPR803,Threonine proteases,Serine proteases,IPR-803,Ser/Thr Protease,Serine endopeptidases
- CBNumber
- CB84718624
- Molecular Formula
- C27H23N3O4
- Formula Weight
- 453.49
- MOL File
- 892243-35-5.mol
IPR-803 Property
- Boiling point:
- 749.0±60.0 °C(Predicted)
- Density
- 1.401±0.06 g/cm3(Predicted)
- pka
- 4.17±0.10(Predicted)
- form
- Solid
- color
- Brown to reddish brown
N-Bromosuccinimide Price
- Product number
- CS-0034598
- Product name
- IPR-803
- Purity
- 98.03%
- Packaging
- 5mg
- Price
- $330
- Updated
- 2021/12/16
- Product number
- CS-0034598
- Product name
- IPR-803
- Purity
- 98.03%
- Packaging
- 10mg
- Price
- $550
- Updated
- 2021/12/16
- Product number
- CS-0034598
- Product name
- IPR-803
- Purity
- 98.03%
- Packaging
- 25mg
- Price
- $980
- Updated
- 2021/12/16
IPR-803 Chemical Properties,Usage,Production
Uses
IPR-803 is a potent inhibitor of the uPAR·uPA protein-protein interaction (PPI). IPR-803 binds directly to uPAR with sub-micromolar affinity. IPR-803 displays anti-tumor activity[1].
in vivo
IPR-803 (200 mg/kg; i.g.; three times a week; for 5 weeks) impairs breast cancer metastasis, but no statistical significance to the differences in body weight between treated and untreated[1].
IPR-803 has a low oral bioavailability at 4 percent, and remains high concentration even after 10 hours in tumor tissue[1].
IPR-803 exhibits a half-life (t1/2) of 5 hours[1].
| Animal Model: | NSG mice with MDA-MB-231 cells xenograft[1] |
| Dosage: | 200 mg/kg |
| Administration: | Oral gavage; three times a week; for 5 weeks |
| Result: | Impaired metastasis to the lungs. |
| Animal Model: | NOD/SCID mice[1] |
| Dosage: | 200 mg/kg (Pharmacokinetic Study) |
| Administration: | Oral administration |
| Result: | t1/2=5 hours. |
References
[1] Mani T, et al. Small-molecule inhibition of the uPARuPA interaction: synthesis, biochemical, cellular, in vivo pharmacokinetics and efficacy studies in breast cancer metastasis. Bioorg Med Chem. 2013 Apr 1;21(7):2145-55. DOI:10.1016/j.bmc.2012.12.047
IPR-803 Preparation Products And Raw materials
Raw materials
Preparation Products
IPR-803 Suppliers
- Tel
- 021-65675885 18964387627
- Fax
- 021-65675885
- info@efebio.com
- Country
- China
- ProdList
- 9803
- Advantage
- 58
- Tel
- 021-61312847; 18021002903
- Fax
- QQ:3008007432
- 3008007409@qq.com
- Country
- China
- ProdList
- 89689
- Advantage
- 60
- Tel
- +1-781-999-5354; +17819995354
- marketing@targetmol.com
- Country
- United States
- ProdList
- 32467
- Advantage
- 58
- Tel
- 18818260767
- Fax
- QQ 3610331285
- sales@chemegen.com
- Country
- China
- ProdList
- 11218
- Advantage
- 58
- Tel
- 4008200310
- marketing@tsbiochem.com
- Country
- China
- ProdList
- 24960
- Advantage
- 58
- Tel
- 025-85560043 15850508050
- Fax
- 025-85563444
- cindy.huang@synzest.com
- Country
- China
- ProdList
- 12000
- Advantage
- 58
- Tel
- 18024082417
- market@ubiochem.com
- Country
- China
- ProdList
- 9835
- Advantage
- 58
- Tel
- 400-821-026
- Sales@sangon.com
- Country
- China
- ProdList
- 6813
- Advantage
- 58
- Tel
- 51288865780
- sales@biosynth.com
- Country
- China
- ProdList
- 6051
- Advantage
- 58
- Tel
- 18916360931 18916360931
- 2596183085@qq.com
- Country
- China
- ProdList
- 17238
- Advantage
- 58